

PERSEPHONI™

FOR IMMEDIATE RELEASE

Monarch Therapeutics and Persephoni BioPartners Announce Strategic Collaboration to Drive Therapies to the Clinic

Princeton, NJ and Morrisville, NC — Monarch Therapeutics, Inc., a biotechnology company pioneering next-generation adaptor CAR T-cell therapies for solid tumors today announced a strategic collaboration with Persephoni BioPartners. This partnership marks a significant step forward in Monarch's mission to develop targeted therapies.

As a member of Persephoni's venture studio, Monarch will gain access to Persephoni's scientific, operational, and capital resources to accelerate the advancement of its pipeline programs and platform technologies. Persephoni, known for its integrated venture model and deep expertise in immunology and precision medicine, will provide Monarch with strategic services, guidance, and infrastructure to support its next stage of growth.

"Partnering with Persephoni is a transformative milestone for Monarch," said Christopher Potts, CEO of Monarch Therapeutics. "Their team brings an exceptional combination of scientific depth, operational experience, and entrepreneurial focus. We're confident that this collaboration will accelerate our path toward delivering meaningful therapies to patients."

"We're thrilled to welcome Monarch to the Persephoni venture studio," said Hilary Schultz, Chief Executive Officer at Persephoni BioPartners. "Their innovative approach to creating modular, personalized cell therapies aligns perfectly with our strategic focus areas. Together, we aim to unlock new therapeutic opportunities in complex disease areas where patients still lack effective treatments."

The collaboration will initially focus on advancing Monarch's lead candidates into clinical development, as well as expanding its discovery engine to pursue novel targets across indications.

About Persephoni BioPartners

Persephoni BioPartners is a venture creation and development firm focused on launching and scaling transformational biotech companies. Through its hybrid private equity and venture model,

PERSEPHONI™

Persephoni partners with entrepreneurs and scientists to build high-impact businesses grounded in breakthrough science. For more information visit, <https://persephonibio.com>

About Monarch Therapeutics Inc.

Monarch Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation immunotherapies. The company's proprietary adaptor platform enables precise, programmable control of cell-based therapies, expanding their reach and dynamic disease targeting across a broad range of therapeutic areas. With a focus on solid tumors, Monarch Therapeutics implements its adaptor platform to drive universal CAR-T cell therapies with leading tunability, multi-antigen targeting, and control. For more information, visit <https://monarchtherapeutics.com/>